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Abstract
Background: The etiology of hemangiosarcoma remains incompletely understood. Its common occurrence in
dogs suggests predisposing factors favor its development in this species. These factors could represent a
constellation of heritable characteristics that promote transformation events and/or facilitate the establishment of a
microenvironment that is conducive for survival of malignant blood vessel-forming cells. The hypothesis for this
study was that characteristic molecular features distinguish hemangiosarcoma from non-malignant endothelial
cells, and that such features are informative for the etiology of this disease.
Methods: We first investigated mutations of VHL and Ras family genes that might drive hemangiosarcoma by
sequencing tumor DNA and mRNA (cDNA). Protein expression was examined using immunostaining. Next, we
evaluated genome-wide gene expression profiling using the Affymetrix Canine 2.0 platform as a global approach
to test the hypothesis. Data were evaluated using routine bioinformatics and validation was done using
quantitative real time RT-PCR.
Results: Each of 10 tumor and four non-tumor samples analyzed had wild type sequences for these genes. At the
genome wide level, hemangiosarcoma cells clustered separately from non-malignant endothelial cells based on a
robust signature that included genes involved in inflammation, angiogenesis, adhesion, invasion, metabolism, cell
cycle, signaling, and patterning. This signature did not simply reflect a cancer-associated angiogenic phenotype, as
it also distinguished hemangiosarcoma from non-endothelial, moderately to highly angiogenic bone marrow-
derived tumors (lymphoma, leukemia, osteosarcoma).
Conclusions: The data show that inflammation and angiogenesis are important processes in the pathogenesis of
vascular tumors, but a definitive ontogeny of the cells that give rise to these tumors remains to be established. The
data do not yet distinguish whether functional or ontogenetic plasticity creates this phenotype, although they
suggest that cells which give rise to hemangiosarcoma modulate their microenvironment to promote tumor
growth and survival. We propose that the frequent occurrence of canine hemangiosarcoma in defined dog breeds,
as well as its similarity to homologous tumors in humans, offers unique models to solve the dilemma of stem cell
plasticity and whether angiogenic endothelial cells and hematopoietic cells originate from a single cell or from
distinct progenitor cells.
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Background
The study of malignant soft tissue sarcomas that arise
from, or resemble constituents of blood vessels in
humans, including angiosarcomas (hemangiosarcomas
and lymphangiosarcomas), Kaposi sarcomas, heman-
gioendotheliomas, and hemangiopericytomas, is compli-
cated by their infrequent occurrence [1]. Despite their
relatively low incidence, angiosarcomas are associated
with more frequent metastasis and greater patient mor-
bidity and mortality than other soft tissue sarcomas.
The clinical significance of angiosarcomas is magnified
because of their aggressive biological behavior and their
association with medical or occupational exposures to
ionizing radiation and a variety of industrial and agricul-
tural chemical agents [1-3].
Other species also develop hemangiosarcomas. From a
comparative perspective, hemangiosarcomas occur rarely
in mice as a spontaneous disease, but the incidence is
significantly increased in the B6C3F1 hybrid strain after
exposure to various classes of pharmaceuticals, making
these tumors a factor in risk assessment for drug devel-
opment [2]. Dogs are the only species where idiopathic
(spontaneous) hemangiosarcoma occurs commonly. This
disease has been estimated to account for up to 7% of
malignant canine tumors [4], which would roughly
translate into >50,000 diagnoses per year in the United
States. Regardless of species, treatment options for
angiosarcoma and hemangiosarcoma are limited, and
outcomes are generally unrewarding [5-7]. The standard
of care in both humans and dogs includes surgery and
adjuvant chemotherapy. The median and 5-year survival
rates for human patients with angiosarcoma are
reported to be approximately 2 to 2.5 years and 30%,
respectively [1]. In dogs, the prognosis is equally grave:
even though 10-15% of dogs with this disease survive 12
months or longer, most die within 3-months of their
diagnosis [4]. Despite anecdotal success using immu-
notherapy, as well as novel chemotherapy and antiangio-
genic strategies to treat canine hemangiosarcoma [8-13],
the past 30 years have brought no improvements in sur-
vival for dogs with this disease [14].
The lack of effective treatments for humans and dogs
with angiosarcoma and hemangiosarcoma is largely due
to our incomplete understanding of the factors that pro-
mote the survival, growth, and metastases of these
malignancies. Inflammation, hypoxia, and angiogenesis
all might contribute to the pathogenesis of idiopathic
hemangiosarcoma, or of hemangiosarcoma associated
with exposure to non-genotoxic agents in each of the
target species. The link between inflammation and can-
cer is becoming clearer, with macrophages and macro-
phage-derived cytokines playing a central role in
modulating the tumor microenvironment to facilitate
both tumor survival and metastasis [15-17]. Macrophage
activation and local tissue hypoxia are central compo-
nents of the proposed mechanism of action that drives
hemangiosarcoma in rodents exposed to a diverse array
of compounds such as 2-butoxyethanol, peroxisome
proliferator-activated receptor (PPAR) agonists and
pregabalin [2]. Parallels have been drawn between
canine hemangiosarcoma cells and neoangiogenic
endothelial cells in tumors [18,19]. Vessel formation in
hemangiosarcoma resembles the morphology of imbal-
anced, chaotic growth and maturation of neoangiogenic
vessels seen in cancer, which is at least partly driven
by pro-angiogenic factors such as vascular endothelial
growth factor-A (VEGF) [18,20]. In fact, hemangiosar-
coma cells elaborate growth factors that promote
angiogenesis, including not only VEGF, but also plate-
let-derived growth factor-b (PDGFb), and basic fibro-
blast growth factor (bFGF) in vitro [14,18,19,21].
Signaling by each of these growth factors is partly
dependent on activation of the phosphoinositide 3-
kinase (PI3K) pathway, providing a possible connection
between the processes of inflammation, hypoxia, and
angiogenesis in the pathogenesis of hemangiosarcoma
[22]. In this regard, mutations of the PI3K antagonist,
PTEN, are common in canine hemangiosarcoma; how-
ever they are restricted to the C-terminal domain and
do not affect the phosphorylation of Akt that occurs
downstream from PI3K signaling [23]. While it is possi-
ble that mutations in the C-terminal domain reduce the
stability of PTEN [24] or increase motility, and hence a
cell’s invasive potential [25,26], the precise effects of
these mutations in canine hemangiosarcoma remain
unclear. The genetic basis of abnormal patterns of
growth and signaling require further characterization.
Mutational events have been documented in sporadic
angiosarcomas of humans and hemangiosarcomas of
mice and dogs, including cancer-associated genes such
as PTEN, Ras, VHL, p53, and connexin, [27-34]. In the
case of canine hemangiosarcoma, PTEN mutations did
not fully explain the increased levels of VEGF or other
growth factors [18,23], prompting additional assessment
of potential roles for mutations that inactivate VHL or
that activate Ras, as both can lead to elevated VEGF
production. Yet, another possibility was that non-
malignant cells are responsible for VEGF production in
canine hemangiosarcoma [35], especially since co-
existence of tumor cells with inflammatory cells is a
common feature of this disease, and in some cases, the
inflammatory cells may provide the principal source of
VEGF [23]. In this scenario, VEGF-producing inflamma-
tory cells could be reactive leukocytes incited by patho-
logic effects of tumor (e.g., tissue destruction), or
macrophages and myeloid cells that are intrinsic compo-
nents of the tumor microenvironment [17,35]. A third
possibility is that hemangiosarcomas originate from a
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multipotent bone marrow progenitor that can differenti-
ate along the myeloid lineage [36,37], and these cells
thus could reflect the ontogeny of the malignant cells
and their plasticity to differentiate into multiple cell
types.
Here, we show in an isolated in vitro system that expres-
sion of genes involved in inflammation, angiogenesis,
adhesion, invasion, metabolism, cell cycle, signaling, and
patterning can distinguish hemangiosarcoma cells from
non-malignant endothelial cells. While the data do not
distinguish whether functional or ontogenetic plasticity
creates this phenotype, they suggest the factors that
hemangiosarcoma cells use to communicate with their
microenvironment are distinct from those used by non-
malignant endothelial cells. To our knowledge, this is the
first report that establishes differences between hemangio-
sarcoma and non-malignant endothelial cells in any spe-
cies, highlighting biochemical and metabolic pathways that
may be amenable to therapeutic targeting for this disease.
Methods
Samples
Between 2000 and 2005 we received samples from 63
pet dogs with pathologically confirmed hemangiosar-
coma (N = 58) or pathologically confirmed splenic
hematoma (N = 5). Eighteen tumors and four splenic
hematomas included fresh, viable tissue as part of the
submission, while the remainder included only fixed or
frozen tissue. For each sample set that included viable
tissues, we cultured a portion of tissue under conditions
that favored growth of endothelial cells to derive cul-
tured cell lines from tumors or low passage cultures
from the splenic hematomas [18,23,36]. We derived
such cultures successfully from 10/18 hemangiosarco-
mas and from four of five splenic hematomas, which
were used for the analyses described in this study (see
Additional File 1, Table S1). The morphology of the
resulting cell lines was variable [18], but each expressed
antigens that are characteristically expressed by blood
vessel-forming cells [18,23,36]. To ensure there were no
hidden biases in the sample population, we examined
descriptive statistics between the 14 dogs from which
we established cells in culture and from the 49 dogs for
which we did not establish cell lines. There were no sig-
nificant differences between the two groups when com-
paring geographic origin, gender, age at diagnosis,
anatomic location of the primary tumor or lesion, num-
ber of dogs treated, or outcome. The characteristics of
both populations also were similar to those described
elsewhere [38]. For tumors, cells from earliest passages
available were used for the experiments. High molecular
weight genomic DNA and total RNA were isolated as
described [39,40]. Only two of the dogs whose samples
were used for the microarray experiments (Frog and
Journey) were related within five generations, and they
were separated by three generations (Frog was Journey’s
paternal “great aunt”), reducing the likelihood of lineage
bias. To confirm the data from the initial 10 hemangio-
sarcoma samples and to assess how the results from cell
lines correlated with data from intact tissues, we estab-
lished four additional cell lines from two dogs with
hemangiosarcoma and used these, as well as three inde-
pendent whole tissue samples in microarray experi-
ments. One cell line (Emma-HSA) was previously
reported [40]. Three additional lines, called Jack-liver
HSA, Jack-spleen HSA, and Jack-heart HSA were estab-
lished form one dog with metastatic hemangiosarcoma
(spleen, liver, and heart). The tissue samples all were
from splenic tumors where sufficient, high quality snap-
frozen and cryopreserved material was available.
Peripheral blood samples were obtained from dogs with
hemangiosarcoma or other tumors by a licensed veterinar-
ian or an animal health practitioner as part of medically
necessary (biopsy) procedures prior to initiating therapy or
at the time of necropsy. Samples from healthy dogs
obtained as part of routine diagnostic or well-health pro-
cedures were used as controls. Non-hemangiosarcoma
diagnoses included non-Hodgkin lymphoma, leukemia,
and osteosarcoma. Every sample was obtained with owner
consent through protocols reviewed by appropriate Insti-
tutional Animal Care and Use Committees.
Assessment of VHL and Ras gene expression
The procedures used to clone and confirm the sequence
of canine VHL are described in the Supplementary
Methods (see Additional File 2; Genbank ID numbers
GU563722 and GU563723). The nucleotide sequence
and the translated amino acid sequence for canine VHL
are in Additional File 3, Figure S1. The conditions for
RT-PCR to amplify the complete coding sequence from
the ATG start codon to the TGA stop codon included
forward primer, CGTTGTCTAGGCTCCGGG, reverse
primer, GGCTGAGACTCAGGAGTGC, and annealing
temperature of 60°C. We used RT-PCR conditions
described previously to amplify the complete coding
sequence for canine N-Ras, K-Ras, and H-Ras [41].
Gene expression profiling
Approximately 2.5 μg of RNA were labeled using the
Affymetrix labeling protocol (Affymetrix, Santa Clara,
CA, USA), with cRNA samples hybridized to Affymetrix
Canine_2 gene expression chips as described [40]. One
sample was done in duplicate (2 chips) to control for
batch effects. The concordance between the data from
duplicate chips was >97%. The theoretical principles and
the empirical observations used to support the sample
size for these experiments a priori were essentially as we
described before [40]. The PowerAtlas (http://www.
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poweratlas.org, ref. [42]) allowed us to obtain an empiri-
cal estimate that the imbalanced sample sets used for
these experiments with 10 hemangiosarcomas and three
splenic hematomas should provide >85% power at a =
0.05 to identify true positives, although the power to
identify true negatives could be lower. Bioinformatic
analysis followed previously described protocols, includ-
ing normalization, filtering, assignments of functional
ontogeny, and gene set enrichment for pathway identifi-
cation [40]. All data are available through the Gene
Expression Omnibus http://www.ncbi.nlm.nih.gov/geo/
with access number GSE22129 or by searching the term
“hemangiosarcoma”. These data also are combined with
those from our previous study [40] in a GEO Super-
Series (accession number GSE23760). Ingenuity Pathway
Analysis (IPA) software v8.6 (Ingenuity Systems, Red-
wood City, CA, USA) was used to define functions and
canonical pathways of genes identified by GSEA using
BH multiple testing corrections to assess significance.
Real-time quantitative RT-PCR (RT-qPCR)
RT-qPCR for TIMP-1, PLZF, and FN-1 was performed at
50°C for 2 min, 95°C for 10 min, and then 40 cycles of
95°C for 15 s and 60°C for 1 min per cycle. Forward pri-
mers, reverse primers, and Taqman probes (5’ to 3’ orien-
tation) were: for TIMP-1 GAGAGCGTCTGCGGAT
ACTTG, TCCGGCGACCAGAAACTC, and ACAGGTC
CCAGAACC, for PLZF ACGGACATGGCCGTCTTC,
CGCTCTGCGCCTGGAA, and TGCTGTGTGGGAAGC,
and for FN-1 GCCAGCCCCTGATTGGA, CCAGCG
GTGGCAGTGAAC, and CCCAGTCCACAGGTATA.
Each reaction was done in triplicate and normalized to
endogenous 18 S gene using Taqman Fast Reagent Starter
Kit (ABI).
Immunostaining
Immunohistochemistry on formalin-fixed and paraffin-
embedded tumor samples and immunocytochemistry on
freshly grown cells were done at IHC Services (Smith-
ville, TX, USA) as described [23,43]. Antibodies were
selected based on known cross-reactivity against the
canine protein or on their generation using highly con-
served regions of the protein as immunogens. Specifi-
cally, we used antibodies against VHL (antibody G-7,
Santa Cruz Biotechnology, Santa Cruz, CA, USA),
pan-Ras (all family members, antibody C-4, Santa Cruz
Biotechnology), Erk 1/2, (antibody MK1, Santa Cruz
Biotechnology), phospho-Erk 1/2 (antibody 12D4, Santa
Cruz Biotechnology), and platelet-derived growth factor
receptor-b (PDGFRb, antibody P20, Santa Cruz Biotech-
nology) for immunostaining. Expression of HIF-1a was
verified by immunoblotting as described [23,40] using
an anti- HIF-1a antibody from Novus Biologicals (Little-
ton, CO, USA).
Results
Mutations of VHL and Ras genes are infrequent in canine
hemangiosarcoma
We sequenced the complete coding domains for VHL,
N-Ras, K-Ras, and H-Ras from 10 canine hemangiosar-
coma cell lines and from four lines derived from splenic
hematomas. These genes are infrequently mutated in
angiosarcomas of humans and hemangiosarcomas of
rodents. Mutations in these genes appear to be similarly
infrequent in canine hemangiosarcoma, as each of the
tumor samples, as well as the splenic hematoma samples
we evaluated in this study had wild-type sequence for VHL
and for the three Ras family genes. Expression of VHL and
Ras proteins was confirmed by immunostaining in the cell
lines (Figure 1), and VHL expression also was verified in
eight archival samples representing original tumors used to
derive the cell lines by immunohistochemistry (Figure 2).
VHL expression in the splenic hematomas was restricted
to endothelial cells (shown by black arrows in Figure 2),
whereas the protein was uniformly detectable in heman-
giosarcoma cells, but not in stromal or inflammatory cells,
in the tumor sections. Hemangiosarcoma cell lines
expressed HIF1a at approximately comparable levels to
those seen in human ACHN renal cell carcinoma cells
with wild type VHL (data not shown), suggesting there
was no abnormal accumulation of this protein. Immunos-
taining of Erk1 and Erk2 proteins, which operate down-
stream from Ras, was barely detectable in each of three cell
lines examined, and of the three canine hemangiosarcomas
cell lines, only “Frog” showed evidence of constitutively
active Erk1 and Erk2 based on positive staining by the pre-
sence anti-phospho-Erk antibody (Thr 202 and Tyr 204).
Phospho-Erk1/2 proteins in this cell line were restricted to
the cell membrane in areas of cell-to-cell contact at the
periphery of large multicellular clusters (see Additional
File 4, Figure S2), and were not seen in individualized cells
or in cells forming smaller clusters, suggesting activation
was probably mediated by intercellular signaling. These
findings provide further evidence that abnormal activation
of the VHL and Ras pathways is not a common occurrence
in canine hemangiosarcoma. Indeed, the probability that
we would observe no mutations if the sample size had a
binomial distribution and the mutation rate were high as
0.28 is approximately 1%. Therefore, we conclude that the
frequency of VHL or Ras mutations in sporadic canine
hemangiosarcoma is unlikely to exceed 30%.
Gene expression analysis segregates canine
hemangiosarcoma cells from proliferating endothelial
cells of splenic hematoma
We hypothesized that hemangiosarcoma cells would be
distinguishable from non-malignant proliferating
endothelial cells, such as those found in splenic hema-
toma, based on gene expression profiles. We further
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hypothesized that these profiles would be informative
for the pathogenesis of this disease. We chose to evalu-
ate gene expression profiles in the low passage cultured
cells, which we surmised would provide a more homo-
geneous population than fresh tumor samples by
excluding non-malignant stromal components and
inflammatory cells, mitigate genes associated with phe-
notypic endothelial commitment, and diminish the influ-
ence of differential proliferative signatures. Nonetheless,
it was likely that hemangiosarcoma cells would preserve
signatures associated with incomplete differentiation.
RNA from ten hemangiosarcomas and from three sple-
nic hematomas was processed and hybridized to
Canine_2 Affymetrix chips. After data were normalized
and filtered, a list of 14,028 genes remained that allowed
comparisons between the two sample sets. Hierarchical
clustering from this list separated the samples into two
main groups, consisting of hemangiosarcoma and splenic
hematoma (Figure 3A). Within the hemangiosarcoma
group, two major subgroups also separated golden retrie-
vers from non-golden retrievers [40]. When the False
Discovery Rate (FDR) was set to <0.1, we uncovered a
Figure 1 Expression of VHL and Ras proteins in canine hemangiosarcoma cell lines. DD-1, Dal-4, and Frog canine hemangiosarcoma cell
lines were cultured in chamber slides and stained with an irrelevant control antibody, or with antibodies against VHL or pan-Ras as indicated on
the left. Cells were visualized using bright field microscopy at low magnification (10× objective, BF 10×) and staining in the same fields was
visualized using epifluorescence (FL 10×). Bars = 200 μm. Right panels show photomicrographs of DD-1 cells under bright field illumination at
high magnification (40 × objective, BF 40×) to illustrate the localization of VHL to the cytoplasm and the localization of Ras predominantly to the
inner plasma membrane (red staining). Bars = 20 μm.
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58-probe signature representing 30 genes, four predicted
genes, and nine transcribed loci, which was differentially
expressed between both groups. A heatmap using these
differentially (over- or under-) expressed probes is shown
in Figure 3a, and the genes are listed in the order they
appear in the heatmap in Table S2 (see Additional File
5). A functional annotation is provided in Table S3 (see
Additional File 6).
Microarray data were validated by rigorous statistical
tests; however, we verified changes by RT-qPCR of
TIMP-1 and PLZF, two genes expressed abnormally in
other cancers [44,45]. TIMP-1 expression was estimated
to be, on average, 7 fold higher in hemangiosarcomas
than in splenic hematomas based on microarray data,
whereas RT-qPCR showed changes as large as +800 fold
(Figure 3B). In the case of PLZF, expression in heman-
giosarcoma was estimated to be, on average, 10.5 fold
lower in hemangiosarcomas than in splenic hematomas
based on microarray data, and indeed, PLZF levels were
10 to 500 fold lower in hemangiosarcoma samples based
on RT-qPCR.
According to the Power Atlas prediction, the likeli-
hood that genes on our list were true positives was high,
but the expected discovery rate might have been low.
Figure 2 Expression of VHL and PDGFRb proteins in canine splenic hematoma and in canine hemangiosarcoma tissues. Serial 5-μm
sections from paraffin-embedded splenic hematomas or hemangiosarcomas were stained with an irrelevant control antibody, or with antibodies
against VHL or PDGFRb as indicated on the left. Photomicrographs represent similar or contiguous regions within each tissue at 640×
magnification. Two samples of splenic hematomas and eight samples of canine hemangiosarcoma were stained for VHL. Both splenic
hematomas and five hemangiosarcomas were stained for PDGFRb. One of the splenic hematomas and two hemangiosarcomas (the tumors used
to derive the DD-1 and Dal-4 cell lines) are shown to illustrate the observed patterns. Expression of relevant antigens is indicated by red staining.
VHL staining in the splenic hematomas was restricted to blood vessel lining cells (black arrows), whereas in the hemangiosarcomas, VHL staining
was seen diffusely in the tumor cells, but not in associated inflammatory cells. In contrast, PDGFRb staining was seen in blood vessel lining cells
in the splenic hematomas, but was seen both in tumor cells and in associated inflammatory cells in the hemangiosarcomas (blue arrows). Bars =
20 μm.
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We selected Fibronectin (FN-1), a gene involved in
wound healing, blood coagulation, and cancer metastasis
[46], as a representative candidate that showed signifi-
cantly different expression in hemangiosarcoma and
splenic hematoma, but did not meet the initial FDR cri-
teria. FN-1 expression in hemangiosarcoma samples was
estimated to be, on average, 2 fold higher in hemangio-
sarcomas than in splenic hematomas based on microar-
ray data, and RT-qPCR confirmed expression was
increased by 2 to 12 fold (Figure 3B).
When all of the genes showing significantly different
levels of expression were arranged according to their
cytogenetic location, hemangiosarcoma genomes showed
remarkable underexpression (commonly absent) com-
pared to the splenic hematoma genomes (Figure 3C).
These changes are similar to those reported for various
other tumors [47] and could be caused by deletions,
translocations, or epigenetic changes such as methyla-
tion. These data also show the sensitivity of this
approach. There were 3 females in the hemangiosar-
coma group (30%) and 2 females in the splenic hema-
toma group (67%). As one would predict from these
ratios, genes in the X chromosome appeared to be con-
sistently underexpressed in the hemangiosarcoma group.
Canine hemangiosarcoma gene signatures are distinct
and do not reflect simply malignant transformation
To establish whether these changes were specific to
hemangiosarcoma, or if they were simply associated with
any malignancy, we compared array data from six heman-
giosarcoma samples with data from five osteosarcomas,
three leukemias, and 13 non-Hodgkin lymphomas. We
used samples from golden retrievers exclusively as a way
to minimize the potential bias that breed (genetic back-
ground) might introduce on gene expression signatures
[40,48]. This comparison yielded 1,092 probes with FDR <
0.001, suggesting that indeed, hemangiosarcomas have
Figure 3 Canine hemangiosarcoma cells segregate from non-
malignant splenic hematoma cells via their gene expression
profile. (A) Hierarchical clustering and heat map of differentially
expressed genes in 10 hemangiosarcoma samples versus three
splenic hematoma samples. Increasing red intensity indicates
increased gene expression and increasing green intensity indicates
decreased gene expression as shown in the scale bar. The scale
(-1 to +1) reflects variation in intensity from the mean (0) and not
fold-change. Fold-change differences are shown in Table S2. (B)
Quantitative expression and graphical representation of 2 genes
shown in Figure 2A (TIMP-1 and PLZF) and 1 additional gene (FN-1)
that were differentially expressed between hemangiosarcoma and
splenic hematoma cells. Samples were evaluated for gene
expression changes by RT-qPCR, normalized to the endogenous 18
S gene. One sample originating from a dog with splenic hematoma
was set to the unitary value (1.0) and used as the calibrator; gene
expression is presented as the log fold-change compared to the
calibrator. (C) Genes whose expression was significantly different (p
<0.05) between hemangiosarcomas and splenic hematomas based
on analysis of variance of the complete filtered lists were plotted
according to their cytogenetic location on the 38 canine autosomes
and the X chromosome. The color intensity for each chromosome
(red-over represented to gray to blue-under represented) represents
the sum of all changes.
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unique gene expression signatures. Specifically, if we lim-
ited the analysis to the 58 differentially expressed probes
from the analysis shown in Figure 3A and Table S2,
hemangiosarcomas were readily segregated from the other
tumors and from the non-malignant endothelial cells
(Figure 4A), suggesting at least ~30 genes show relatively
unique and consistent patterns of coordinate expression in
hemangiosarcoma cells. Moreover, hemangiosarcoma
samples also were readily distinguishable from the non-
hemangiosarcoma samples by principal component analy-
sis using unfiltered data (Figure 4B).
Genes that were expressed at significantly higher levels
in hemangiosarcomas than in non-hemangiosarcoma
tumors (osteosarcoma, non-Hodgkin lymphoma, and
leukemia) included VEGFA, TIMP-1, FN-1, ADAM9,
PDGFC, MMP14, TNFa, and acid ceramidase, which
also were more highly expressed in hemangiosarcomas
than splenic hematomas. This gene signature suggested
inflammatory and angiogenic pathways play a significant
role in the pathogenesis of hemangiosarcoma. Moreover,
hemangiosarcomas might preferentially utilize survival
pathways involving ceramide signaling, which may be
less commonly used by other tumors.
Pathway analysis provides insight into hemangiosarcoma
tumor biology
Hierarchical clustering and other similar analyses are
informative to determine overall similarity between
samples and to separate samples into defined groups
based on molecular signatures. They do not, however,
provide definitive information regarding how the genes
may be functionally related and thus contribute to the
biology of the tumors. Several bioinformatic approaches
have been developed to infer such functional relation-
ships, including gene ontology (ONTO) and gene set
enrichment analysis (GSEA). We predicted this
approach would identify abnormally expressed genes
concentrated in pathways that reflect the origin and pro-
gression of this disease. We used the ONTO/express
software to identify functional pathways for each gene in
Table S2. These pathways are commonly dysregulated in
cancer; however, ONTO analysis failed to identify path-
ways that would converge on one or a few recurrent
abnormalities.
GSEA is a robust computational tool that can uncover
subtle alterations in complex diseases by utilizing
expression data to characterize gene signatures within
pathways. Pathways that defined cellular processes
underlying hypoxia, cancer, or inflammation were highly
enriched in hemangiosarcoma (Table 1). We used the
leading edge subset to compare genes from each path-
way to 30 other pathways that showed enrichment a
FDR < 0.05. One hundred and fifty-seven genes were
present in at least one pathway, 31 were recurrently pre-
sent in at least two pathways, and 23 were in at least
three pathways. The results from these top 23 genes
Figure 4 Hemangiosarcoma is distinguishable from both non-malignant and other malignant tumors. (A). Hierarchical clustering of
tumor samples or non-malignant lesions (hematoma) from golden retrievers. Tumor samples were from osteosarcoma cell lines (OSCA), primary
leukemia (ALL-Acute lymphoblastic leukemia or CLL-Chronic lymphocytic leukemia) or non-Hodgkin lymphoma (diffuse large B-cell lymphoma,
marginal zone lymphoma, or T-zone lymphoma) cells, or hemangiosarcoma cell lines (HSA). Hierarchical clustering was done using the restricted
probe list from Table S2. (B) Principal component analysis (PCA) of tumor samples and non-malignant lesions described in (A), except analysis
was done using all data points.
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show that IL8 was enriched in 16 of the 30 pathways,
CD44 in 12, CDH2 in nine, IL6 in eight, VEGFA,
PLAU, PTGS2 and FN-1 in seven each, TNC in six,
PTGER4 and SSP1 in five, SLC2A3, ADM, CCND1, and
MMP1 in four, and several genes, including VCAM1 in
three (Figure 5A).
The recurrent enrichment of proinflammatory cyto-
kines, adhesion molecules, and angiogenic factors in
these cells suggests that modulation of the microenvir-
onment is an essential feature of hemangiosarcoma and
highlights genes that, when treated as a group, may be
prognostically significant and amenable to therapeutic
intervention. We thus examined if the relation of 30
recurrently enriched genes (30 of the 31 genes present
in two or more GSEA pathways were annotated) would
remain when analyzed using Ingenuity Pathway Analyses
(IPA, Table 2). IPA highlighted functional pathways
associated with malignancy (21/30 genes), proliferation
and survival (22/30 genes), migration, metastasis, and
adhesion (22/30 genes), vascular biology and endothelial
ontogeny (16/30 genes), and inflammation (14/30
genes). The top 10 canonical pathways (-log BH p values
>3) were similarly all associated with malignancy and
inflammation. Figure S3 (see Additional File 7) illus-
trates the relationship of six recurrently enriched mole-
cules (IL8, CCND1/Cyclin D1, MMP9, VEGF, VCAM1,
and PTGS2/Cox-2) in one of these canonical pathways
(IL8 signaling), which mediates both angiogenesis and
inflammation.
Finally, to establish the relevance of these molecules
and pathways in vivo, we compared mean expression
levels of 11 annotated genes that were differentially
expressed, and/or differentially enriched, among the
three cultured hematoma samples, 14 hemangiosarcoma
cell lines (the 10 original lines used in the experiment
and four newly established lines), and three whole tissue
samples. We surmised that differences in recurrently
enriched genes where differences in expression were
relatively low would be the most robust indicators of
whether these signatures were relevant to the biology of
hemangiosarcoma or simply altered as a function of cell
culture or anatomical site of origin.
Data from six representative genes are shown in
Figure 5B. In addition, expression levels of IL8Rb are
shown as an example of an invariant control (no differ-
ence in between cultured non-malignant endothelial
cells and hemangiosarcoma cells), and GAPDH and
b-actin were used as housekeeping controls to confirm
that the normalization strategy was valid. Expression of
IL8, TIMP1, and MAOA in whole tissue samples corro-
borated the data from cultured cells. A similar trend
was apparent for the RTK-like orphan receptor, Oncos-
tatin M receptor, and Kinesin family member 5C. On
the other hand, expression of PDGFRb, CD44, and
EPHA2 in hemangiosarcoma cell lines was not predic-
tive for the expression of these proteins in tumor tissues
(Figure 5B), and a similar trend was observed for Neuro-
pilin 1 and v-Myc. We thus investigated the possibility
that these differences might be attributable to stromal
elements in the tumors. As illustrated by in Figure 2,
PDGFRb was expressed predominantly by blood vessel
lining cells in splenic hematomas, whereas in the
tumors, it was expressed generally at lower intensity in
the hemangiosarcoma cells, but it also was expressed in
infiltrating inflammatory cells (blue arrows). This sug-
gests that gene expression by stromal cells contributes
to genome-wide signatures from whole tissues; hence,
supporting the rationale to use enriched cell cultures
and cell lines as an approach to mitigate signatures
from non-tumor components.
Discussion
The mechanisms underlying the origin and progression
of hemangiosarcoma remain unclear. In humans, angio-
sarcoma can be associated with exposure to DNA-
damaging agents or, in the case of Kaposi sarcoma, with
infection by HHV8 in immunosuppressed patients
[1,49]. In mice, hemangiosarcoma can develop in sus-
ceptible strains treated with both genotoxic and non-
genotoxic agents [2]. In dogs, however, the disease
Table 1 Gene set enrichment analysis predicts pathways involved in inflammation, cancer, and hypoxia are important
for hemangiosarcomaa
Gene set Description ES NES FDR
MENSE_HYPOXIA_UP Hypoxia induced genes in HeLa and astrocytes 0.82 2.32 0.000
BRENTANI_CELL_ADHESION Cancer related genes involved in cell adhesion and metalloproteinases 0.67 2.15 0.005
LINDSTEDT_DEND_8H_VS_48H_UP Genes upregulated in stimulated Dendritic cells 0.75 2.15 0.003
HYPOXIA_REVIEW Genes known to be induced by hypoxia 0.62 2.12 0.003
KNUDSEN_PMNS_UP Genes up-regulated in PMNs upon migration to skin lesions 0.73 2.10 0.003
CHIARETTI_T_ALL Genes overexpressed in leukemia 0.61 2.10 0.002
aThe filtered gene list from hemangiosarcoma vs. non-malignant hematomas were compared using the GSEA software. ES (Enrichment Score) is a value that
represents how well the gene set is enriched within the selected gene list. NES (normalized enrichment score) corrects the ES for differences in gene set size and
can be used to compare across gene sets. A high ES or NES indicates that gene set is highly enriched within our gene list. The lists shown are those gene sets
with an NES of 2.10 or higher.
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Figure 5 Gene set enrichment analysis validates the hypothesis that the hemangiosarcoma gene set is involved in hypoxia,
inflammation, and cancer. (A) Bar graph representing the number of gene sets that were enriched in hemangiosarcoma samples versus
splenic hematoma samples. Each of 23 genes on the x-axis was present in the number of gene sets indicated on the y-axis (of 30 where FDR <
0.05). (B) Bar graph representing the direction and magnitude of change in expression for six representative genes (IL8, TIMP1, MAO, PDGFRb,
CD44, EPHA2), one invariant control (IL8Rb) and two housekeeping controls (GAPDH, b-actin) relative to the expression in splenic hematomas.
Data for each group (three splenic hematomas, 14 hemangiosarcoma cell lines, and three hemangiosarcoma tissues) passed quality assurance
using Affymetrix algorithms provided in GeneData Expressionist Refiner. Probe signal levels were quantile-normalized and summarized using the
GeneChip-Robust Multichip Averaging (GC-RMA) algorithm. Normalized files were imported into GeneData Expressionist Analyst so average
expression values for each group, based on multiple-probe hybridization data, could be used in the comparisons.
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occurs sporadically (not as a heritable condition) and
with alarming frequency in the absence of known muta-
gens; a canine gamma herpes virus also has not been
characterized [50]. Indeed, preliminary experiments
using well established methods to detect gamma herpes
viruses [51] yielded no amplification products when
applied to these canine hemangiosarcoma samples
(M. Duckett and M. Cannon, unpublished results), sug-
gesting the etiology of canine hemangiosarcoma does
not involve infection by a gamma herpes virus.
Angiosarcoma in humans and hemangiosarcoma in
dogs are rapidly progressive diseases that are poorly
responsive to conventional therapy. An improved under-
standing of their pathogenesis is needed to develop
effective strategies for prevention and treatment. Our
data suggest that inflammation and angiogenesis
(defined by enrichment of cytokines and adhesion mole-
cules that may be downstream effectors of a single
molecule, like IL8, IL6, or IL1, as well as by robust
upregulation of VEGF, MMPs and TIMPs, PDGF and
PDGFRs, and others) are two general processes that are
central to the pathogenesis of canine hemangiosarcoma.
Here, we first tested the hypothesis that known genes
that regulate VEGF, including VHL and members of the
Ras family were targets of mutation in canine hemangio-
sarcoma. We previously showed that the PTEN/Akt
pathway that appears to be essential in other vascular
tumor models is intact in hemangiosarcoma cells [23].
Our observations that every hemangiosarcoma sample
tested had wild type sequence for VHL, N-Ras, K-Ras,
and H-Ras, no significant elevations of HIF1a, and no
constitutive activation of Erk1 and Erk2 suggest that
dysregulated VEGF production and the aggressive prolif-
eration seen in these tumors are probably mediated by
mechanisms that are independent from abnormalities of
VHL and Ras genes. Recently, Pressler reported similar
findings with regard to mutations of VHL in sporadic
canine renal cell carcinoma [52]. When considered
along with the estimate that solid tumors from humans
(colon and breast carcinomas) carry an average of ~100
gene mutations, these results suggest the probability to
identify recurrent abnormalities by candidate gene
approaches based on lineage similarity or dysregulation
of a single known pathway is low. Indeed, even the
recurrent mutations of the C-terminal domain of PTEN
that we characterized previously were unlikely to be sin-
gularly responsible for the behavior of hemangiosarcoma
or tractable for therapy. We hence tested the hypothesis
that canine hemangiosarcoma would show characteristic
gene expression profiles that would be informative for
etiology and progression.
Genes that regulate cellular metabolism, cell cycle and
cell signaling, cell-cell interactions, survival and apoptosis,
angiogenesis, transcription, and the immune response were
among those dysregulated in hemangiosarcoma cells when
compared to non-malignant proliferating endothelial cells.
Our data specifically highlight pathways that are important
in response to hypoxia or angiogenesis, malignant









1.35E-15 ADM, CCND1, CD44, CDH2, FGF2, FN1, GUCY1A3, HOXA10, IL6, IL8, IL12A, ITGB3, MMP9, NCAM1, PLAU,




1.77E-17 ADM, CCND1, CD44, CDH2, FGF2, FN1, GUCY1A3, IL6, IL8, IL12A, ITGB3, MMP9, NCAM1, PLAU, PTGER4,
PTGS2, S1PR1, SPP1, TGFBR2, TNC, VCAM1, VEGFA
22
Malignant tumor 3.18E-10 CCND1, CD44, CDH2, FGF2, FN1, IL6, IL8, IL12A, ITGB3, MMP9, NCAM1, PLAU, PTGER4, PTGS2, S1PR1,
SPP1, SPTBN1, TGFBR2, TNC, VCAM1, VEGFA
21
Apoptosis 9.50E-10 ADM, CCND1, CD44, CDH2, FGF2, FN1, IL6, IL8, IL12A, ITGB3, MMP9, NCAM1, PLAU, PTGER4, PTGS2,




3.09E-14 CCND1, CDH2, FGF2, FN1, IL6, IL8, IL12A, ITGB3, MMP9, PLAU, PTGER4, PTGS2, S1PR1, TGFBR2, VCAM1,
VEGFA
16
Angiogenesis 3.09E-14 CCND1, FGF2, FN1, IL6, IL8, IL12A, ITGB3, MMP9, PLAU, PTGER4, PTGS2, S1PR1, TGFBR2, VCAM1, VEGFA 15
Adhesion of normal
cells
2.82E-14 CCND1, CD44, CDH2, FGF2, FN1, IL6, IL8, ITGB3, NCAM1, PLAU, SPP1, TGFBR2, TNC, VCAM1, VEGFA 15
Proliferation of
blood cells
3.62E-09 CD44, FGF2, FN1, HOXA10, IL6, IL8, IL12A, ITGB3, MMP9, PTGS2, SPP1, TGFBR2, VCAM1 13
Metastasis 1.11E-12 CD44, CDH2, FGF2, IL6, IL12A, ITGB3, MMP9, NCAM1, PTGS2, SPP1, TGFBR2, VEGFA 12
Inflammatory
response
7.51E-09 CCND1, CD44, FN1, IL6, IL8, MMP9, PLAU, PTGER4, PTGS2, S1PR1, SPP1, VEGFA 12
Inflammation 1.01E-09 CD44, FGF2, IL6, IL8, IL12A, MMP9, PTGER4, PTGS2, SPP1, TGFBR2, VEGFA 11
Infiltration of cells 3.00E-10 CD44, FN1, IL6, IL8, IL12A, ITGB3, MMP9, SPP1, VCAM1, VEGFA 10
aAnnotated genes recurrently enriched in GSEA (> 2 pathways) were analyzed using IPA. Four hundred pathways were identified with a B-H p value < 1 × 10-5.
Virtually all of them were categorized as malignancy, proliferation and survival, vascular processes, and inflammation. The table shows 12 representative
pathways with a B-H p value <1 × 10-8, organized according to number of genes included.
Tamburini et al. BMC Cancer 2010, 10:619
http://www.biomedcentral.com/1471-2407/10/619
Page 11 of 16
transformation, and inflammation. However, altered
expression of genes within these functional categories
could describe virtually any solid tumor (where cyclins,
glucose transporters, and other genes associated with the
mitotic cell cycle commonly show elevated expression)
from its normal counterparts. For example, we recently
showed that elevated expression of CDKN1a (p21) confers
chemoresistance to renal cell carcinomas, which share
common hypoxia-induced, pro-angiogenic signatures with
vascular tumors [53]. The presence of hypoxia-inducible
genes, including HGF, VEGF, bFGF, ADM, and PTGER4
was especially predictable [54,55]; in most tumors, cells
become hypoxic and upregulate genes that promote blood
vessel outgrowth and that control metabolic processes
such as vasodilation that can make cells normoxic. Clonal
evolution in the tumor, and perhaps the environment in
cell culture might favor selection of cells that upregulate
such hypoxia response genes, although expression of these
genes might be inherent to tumors of blood vessel forming
cells.
Recently, Antonescu et al reported that human angiosar-
comas have unique gene expression profiles when com-
pared to other soft tissue sarcomas [56], with notable
enrichment of expression of vascular-specific receptor tyr-
osine kinases TIE1, KDR (VEGFR2), SNRK, TEK, and
FLT1 (VEGFR1), and other genes that are prototypical
endothelial markers including EPHA2 and PDGFb. The
overlap in the gene lists from Antonescu et al [56] and
from our data supports the similarities between human
angiosarcoma and canine hemangiosarcoma. However, an
interesting contrast is Antonescu’s observation that VEGF
expression was lower in angiosarcoma than other soft tis-
sue sarcomas, versus our observation showing enriched
expression of VEGF in hemangiosarcoma cells as com-
pared to non-malignant endothelial cells from splenic
hematomas. This may be due simply to the relative com-
parisons of tumor vs. tumor (by Antonescu et al) and
tumor vs. non-tumor (in this study), which also could
explain the lack of enrichment for vascular-specific recep-
tors in our study, as these molecules would be expressed
both in hemangiosarcoma cells and in non-malignant
endothelial cells. In this respect, an intriguing finding from
our data was the specific enrichment of VEGFR1 in
hemangiosarcoma cells derived from golden retriever
tumors compared to hemangiosarcoma cells derived from
tumors of dogs from other breeds [40], highlighting the
potential utility of the organization and the relative homo-
geneity of dog breeds to understand how heritable factors
might influence tumor pathogenesis.
We also were not surprised to find alterations in the
expression of genes that contribute to malignant transfor-
mation and inflammation, including those that mediate
cellular adhesion, stromal degradation or invasion (metal-
loproteinases), and the pathogenesis of leukemia [57-60].
For example, among the receptor tyrosine kinases found
by Antonescu [56], TIE1 governs expression of inflamma-
tion-associated genes by endothelial cells [61]. IL8 and
IL6, both of which were enriched in our hemangiosarcoma
samples, are recurrently associated with inflammation that
“benefits” tumors (Figure S3), and PTGS2 (a.k.a., COX-2)
is the single most common tumor-associated pro-
inflammatory mediator [16]. It is especially interesting that
expression of PTGS2/COX-2 was enriched in our samples,
as it was previously reported that the enzyme was unde-
tectable by immunohistochemistry in formalin-fixed sam-
ples from canine hemangiosarcomas [62]. There are
several non-mutually exclusive explanations for this find-
ing, including greater sensitivity in the expression microar-
ray platform than immunohistochemistry, inefficient
translation or relatively short protein half-life for Cox-2 in
these tumors, or induction of the gene when cells are
removed from the tumor microenvironment. Additional
work will be required to clarify the role of PTGS2/COX-2
in hemangiosarcoma.
As may be true for hypoxia response genes, upregula-
tion of proinflammatory genes in hemangiosarcoma also
could result from selective pressures to create a favor-
able microenvironment for growth and survival [63].
Tumors have been likened to “wounds that never heal”
[64], which is reflected by shared expression of genes
mediating breakdown of the extracellular matrix, pro-
ductive chronic inflammation, and angiogenesis. For
example FN-1, which was overexpressed in all heman-
giosarcomas evaluated in this set of experiments, is
involved in wound healing, blood coagulation, and can-
cer metastasis. FN-1 also increases MMP9 activity,
which together with urokinase is involved in tumor cell
invasion through the extracellular matrix [65,66]. The
correlation between FN-1 and urokinase is interesting,
since the survival rate of patients and dogs with angio-
sarcoma and hemangiosarcoma, respectively, is excep-
tionally poor due to its exceedingly high metastatic
potential. The role of urokinase and FN-1 to promote
the metastatic phenotype has been the subject of intense
study in other tumors [46,65], but it remains to be
examined in hemangiosarcoma.
On the other hand, angiogenic and inflammatory sig-
natures might reflect the ontogeny of hemangiosarcoma,
rather than selection in the tumor microenvironment.
Inflammatory infiltrates are commonly seen in canine
hemangiosarcoma, but rather than reflecting recruitment
of tumor-associated macrophages and myeloid cells due
to inflammation, perhaps leukocytes may actually be
derived from a population of multipotent progenitor
cells that give rise to hemangiosarcoma. Recent data
suggest that classical cell markers for endothelial and
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myeloid origin cells are less tissue specific than histori-
cally thought [67], possibly due to a the existence of a
shared hematopoietic/endothelial progenitor (the puta-
tive angioblast). We proposed recently that hemangio-
sarcomas might arise from such a cell [36], while Yoder
et al described a similar population of myeloid cells that
are intimate participants in blood vessel formation [37].
This cell is a “vascular mimic” that can express a variety
of cell surface proteins associated with endothelial pre-
cursor cells (CD133, CD34, VEGFR2), but also proteins
that belie hematopoietic origin (CD45, CD14, and
CD115, the CSF1 receptor), that has phagocytic activity,
and that does not contribute to the capillary endothelial
layer in transplanted matrix. The enrichment of the
adhesion molecule CD44, which in combination with
PGE and Wnt-mediated signals may maintain slow
cycling stem cell populations [68], support the possibi-
lity that tumor-initiating cells in hemangiosarcomas
share properties that have been ascribed to “cancer stem
cells” in other tumors.
We conclude that one single lineage may give rise to
both endothelial and hematopoietic progenitors, or alter-
natively, that multiple lineages contribute to blood vessel
formation, including one originating from a restricted
angioblastic progenitor that gives rise to the endothelial
lining cells and one originating from a myeloid progenitor
that is responsible for creating (but not lining) vascular
channels. In this latter scenario, plasticity of adult hemato-
poietic and mesenchymal stem cells would be limited, dif-
ferentiation of myeloid progenitors into endothelial-like
cells would have to reflect functional rather than ontoge-
netic plasticity, and we should consider the possibility that
canine hemangiosarcoma, and by extension, human angio-
sarcoma, might represent a subtype of myeloid sarcomas.
This interpretation is supported by the general enrichment
of genes overexpressed in dendritic cells and in leukemia,
as well as by enrichment of the patterning gene HOXA10
and by the specific downregulation of PLZF in hemangio-
sarcomas; both of which are involved in hematopoietic dif-
ferentiation [45,69]. These results are especially significant
in light of the poor response to treatments that presume
canine hemangiosarcomas are tumors of blood vessels,
and it may signal the need to revise the therapeutic
approach to hemangiosarcoma and angiosarcoma as
tumors of hematopoietic origin.
Preliminary data from our laboratories support the
existence of rare progenitor cells in hemangiosarcoma
that are responsible for propagating our cell lines
in vitro. There also is evidence for cancer stem cells that
are capable of differentiating along different develop-
mental paths to give rise to endothelial cells in chronic
myelogenous leukemia and Burkitt lymphoma [70,71].
Nevertheless, the possibility of vascular mimicry rather
than true vascular differentiation cannot be excluded
because the reverse outcome (endothelial tumors to
hematopoietic cells) has not been documented.
To overcome the potential limitation from use of cell
lines vs. intact tumors, we compared expression of a
restricted, recurrently enriched signature from the heman-
giosarcoma cell lines to whole tumor tissues. The data
suggest that stromal and inflammatory cells can explain
observed difference between these types of samples.
Tumor cells modify the microenvironment and are them-
selves responsive to environmental cues. Nevertheless, to
understand the contribution of the tumor cells to biologi-
cal and pathological processes, it is important to examine
the response in isolated cells. Microdissection of malignant
cells from vascular tumors is difficult without retaining
blood elements and normal angiogenic components that
can be morphologically indistinguishable from the tumor
cells. Conversely, cell lines provide a homogeneous, unlim-
ited resource that can be extensively characterized with
regard to ontogeny. The potential limitation of cell lines is
further mitigated by the use of non-malignant controls to
filter adaptation to ex vivo growth and by use of multiple
samples. Finally, cell lines derived using our protocols
retain the unique properties of the sample specimens and
provide biologically relevant information.
Conclusions
The data show that inflammation and angiogenesis are
important processes in the pathogenesis of vascular
tumors, but a definitive ontogeny of the cells that give
rise to these tumors remains to be established. The data
do not yet distinguish whether functional or ontogenetic
plasticity creates this phenotype, although they suggest
that cells which give rise to hemangiosarcoma modulate
their microenvironment to promote tumor growth and
survival. We propose that the frequent occurrence of
canine hemangiosarcoma in defined dog breeds, as well
as its similarity to homologous tumors in humans, offers
unique models to solve the dilemma of stem cell plasti-
city and whether angiogenic endothelial cells and hema-
topoietic cells originate from a single cell or from
distinct progenitor cells.
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